XENO Stock Overview
Operates as a bio-technology research and development company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Xeno Transplants Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -98.00% |
| Change since IPO | -99.99% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| XENO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.5% |
| 1Y | n/a | 15.6% | 30.7% |
Return vs Industry: Insufficient data to determine how XENO performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how XENO performed against the US Market.
Price Volatility
| XENO volatility | |
|---|---|
| XENO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XENO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine XENO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Elliot Lebowitz | n/a |
Xeno Transplants Corporation operates as a bio-technology research and development company. The company, through a license agreement with Massachusetts General Hospital, intends to develop, manufacture, distribute, and use products and processes for public use with regard to xenotransplantation. The Xenotransplantation is intended to address the problems arising from the limited supply of available human cells, tissues, and organs for transplantation by developing technologies to permit the transplantation of cells, tissues, and organs from other species into humans, such as swine.
Xeno Transplants Corporation Fundamentals Summary
| XENO fundamental statistics | |
|---|---|
| Market cap | US$4.04k |
| Earnings (TTM) | -US$256.37k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs XENO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XENO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$256.37k |
| Earnings | -US$256.37k |
Last Reported Earnings
Jun 30, 2007
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did XENO perform over the long term?
See historical performance and comparison